Leonard M. Bell, co-founder and chief executive of high-flying Alexion Pharmaceuticals Inc. in Cheshire, grossed at least $15.9 million last week on the sale of stock in the Cheshire biopharma, and is on deck to sell $41 million more in coming days, regulatory filings show.
Bell, a cardiologist who left Yale University to develop Alexion’s Soliris for treatment of a rare form of anemia, sold 143,100 shares on Sept. 27-28 pursuant to a sales plan designed to meet the requirements of Rule 10b5-1(c)(1) of the Securities Exchange Act, Alexion said in a recent 8-K filing with the Securities and Exchange Commission.
Alexion shares set a new 52-week high last week, trading in the range of $111 to $116 a share $
Meantime, in a separate 8-K filing Monday, Alexion disclosed that Bell is preparing to sell another batch of 356,900 shares for, among other things, estate and family financial planning.
Bell’s next sale would gross around $41.4 million – before broker’s commissions and income taxes — based on Monday’s late-morning trading of $116.01 a share.
